Improving Care 2018

 

Improving-HIV-Care-18_Theme_Banner_WEB_v3.jpg

Improving-HIV-Care-18_Launch_Web-Button_v1.jpg

About the Program:

Program Overview:

The treatment of patients with HIV infection is a complex process that includes testing, diagnosis, linkage to care, individualized antiretroviral therapy (ART), and the management of co-morbidities (especially hepatitis C co-infection) and other issues. Decisions about the clinical management of HIV patients often require that clinicians understand a wide range of clinical trial data and treatment information if they are to provide the care that is best suited for each patient. This is especially true of ART and includes critically important issues regarding when to start, which antiretrovirals (ARVs) to use and when to switch. 

This two-part medical education program includes a combination of online teaching modules and Q&A sessions with nationally recognized HIV specialists. As a result of participating in this program, physicians and other health care providers will gain a greater understanding of how to provide optimal therapy for patients with HIV infection, thereby increasing the number of patients receiving individualized, optimal ARV therapy, while reducing morbidity and mortality and improving patient outcomes.

The first part of the program includes a choice of three online modules that address: 1) regimen selection for the treatment-naïve patient; 2) regimen selection for the treatment-experienced patient; and 3) prevention and management of common co-morbidities in the HIV- infected patient. Once a module is completed and CME credit has been awarded, the participant will then be offered an opportunity to participate in a Q&A session via text, email or teleconference, scheduled with one of a panel of HIV faculty for a more in-depth discussion of the module topics.

Back to Top

Target Audience:

This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HIV infection.

Back to Top

Learning Objectives:

Upon completion of the program, participants should be able to:

  • Evaluate effective, individualized, and evidence-based ARV therapy to treatment-naïve patients with HIV infection
  • Apply knowledge and skills for selecting the most effective ARV therapy for treatment-experienced patients
  • Discuss important issues in the treatment of HIV-positive patients, including adherence, mental illness, substance abuse, HCV co-infection, and prevention
  • Manage ARV therapy in a variety of patients to address complex medical issues associated with special needs, such as cardiovascular, renal, and bone disease

Release Date: April 30, 2018

Expiration Date: April 30, 2019

Estimated time to complete each Module: 45-60 minutes 

Back to Top

Faculty:

Richard A. Elion, MD
Associate Professor of Clinical Medicine 
George Washington University Medical Center
Washington, DC  

Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research at the University of Pennsylvania
Philadelphia, Pennsylvania

Helena Kwakwa, MD, MPH
Director HIV Clinical Services
Philadelphia Department of Public Health
Ambulatory Health Services
Philadelphia, Pennsylvania

Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois 

Pablo Tebas, MD
Professor of Medicine
Hospital of the University of Pennsylvania
Director, Adult AIDS Clinical Trials Unit (ACTU)
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Ellen Tedaldi, MD
Professor, Medicine, Lewis Katz School of Medicine at Temple University
Director, HIV Program
Temple University Hospital
Philadelphia, Pennsylvania

David A. Wohl, MD
Professor 
Division of Infectious Diseases 
The University of North Carolina at Chapel Hill 
Chapel Hill, North Carolina 

Back to Top

Post-Module Faculty Q&A Session:

Upon the completion of each module, each participant will have an opportunity to have a Q&A Session with one of the program faculty members. This session can take place via email, text or teleconference. The primary purpose of this session will be to answer questions or provide information regarding the completed modules; however, other areas of interest may also be addressed at the discretion of the faculty member.

Note that once a Q&A session is requested, a confirmation will be sent within 48 hours of the request. Once the session request has been confirmed, any text/email requests will then be sent to a faculty member with a response from them given within one week of request. If a teleconference was requested, the scheduling process will begin for a 15-minute call which would be scheduled within one month of the initial request, based on faculty availability.

Click the button below to ask a question or request a Q&A Session with a faculty member once you have completed a module.

Improving-HIV-Care-18_Ask-Request_Web-Button_v1.jpg

 

Back to Top

Joint Accreditation Statement:

Jointly-Accredited-Provider-TM_1000x636  In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
Back to Top

Credit Designation:

Module 1 (Selecting ARVs and Individualizing Care):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 2 (When and How to Modify ART Due to Patient Preference, Availability of New and Improved ARVs, or Virologic Failure):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 3 (Addressing Patient Co-morbidities and Issues that may Interfere with ART Efficacy):  
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest:

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD:
  • Consulting Fees: Gilead, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents: Gilead, Merck, Janssen
Ian Frank, MD:
  • Consulting Fees: Gilead, ViiV
Helena Kwakwa, MD, MPH:
  • No real or apparent conflicts to disclose
Renslow Sherer, MD:
  • Consulting Fees (Advisory Board): Gilead
Pablo Tebas, MD:
  • Royalty: UpToDate
  • Consulting Fees: Merck, Gilead, ViiV
Ellen Tedaldi, MD:
  • No real or apparent conflicts to disclose
David A. Wohl, MD:
  • Consulting Fees: Gilead, ViiV, Janssen
  • Contracted Research: Gilead, ViiV(to University)

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

Back to Top

Method of Participation and Request for Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period, April 30, 2018 through April 30, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 13233. Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Back to Top

Computer System Requirements:

This program requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable version of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player and Real Networks Real One Player.

Back to Top

 

 

 

PIM_small

VE logo 300px 

This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs 


  Jointly provided by the Postgraduate Institute for Medicine and ViralEd, Inc.

Prepare to print

Share this page:

Get link code to this page                     


Back to Top